Drug intelligence / Profile preview

Ginfast Plus

Development stage: Unknown
Lead developer: Logus Pharma
Modality: Small Molecules
Administration: Oral

Overview

Ginfast Plus is a multi-ingredient dietary supplement developed by Logus Pharma, specifically formulated for the management of Polycystic Ovary Syndrome (PCOS) and metabolic disorders associated with insulin resistance. The product contains a synergistic blend of Myo-inositol and D-chiro-inositol, which serve as second messengers in the insulin signaling pathway, helping to restore ovulatory function and improve glucose metabolism. Additionally, it includes Revifast (a proprietary resveratrol formulation), manganese, and folic acid to provide antioxidant support and address nutritional deficiencies common in women with reproductive health issues.

Brand names: Ginfast Plus

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on Ginfast Plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ginfast Plus.

Explore the full profile